AZ'9567 is an orally active MAT2a inhibitor with a pIC 50 of 9.1. AZ'9567 binds to MAT2a allosterically, reduces the synthesis of SAM , decreases SDMA levels, and exerts antiproliferative effects on MTAP -knockout cells. AZ'9567 depletes SAM , causes methionine accumulation in plasma and tissues, triggers adaptive disorders in one-carbon metabolism, transsulfuration metabolism and lipid metabolism, and induces oxidative stress, hepatic steatosis and lipid homeostasis imbalance. AZ'9567 can be used in studies related to MTAP-deficient/deleted cancers.
Products | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.